Wednesday, April 19, 2017 9:45:24 AM
Use of CytoSorb in traumatic amputation of the forearm and severe septic shock
Prof. Heinz Steltzer, Alexander Grieb, Karim Mostafa Anaesthesiology and Intensive Care Medicine, UKH Meidling & Sigmund Freud Private University, Vienna, Austria
Summary:
This case study reports on a 49-year-old patient, who was admitted to the hospital via helicopter transport after a traumatic amputation of his right forearm.
Case presentation
While working on a landfill cleaning surfaces with a high pressure cleaner, the air pressure tube caught his arm and his right forearm was cut off at the elbow joint
The amputate was not damaged macroscopically, however a wide spectrum of various aerobic and anaerobic pathogens was detected in the wound, many of which were multi-resistant. These included, for example, Aeromonas hydrophila, an enterotoxin-producing bacterium which is endemic in the American tropics; Stenotrophomonas maltophilia, a multi-resistant nosocomial pathogen detected in dialysis fluid; and Clostridium subterminale, which has been described in the medical literature only in nine case reports as being pathogenic. This microbiologic diversity was most probably due to the location of the accident being a landfill.
On admission the patient was treated for shock, followed by X-ray examination and immediate replantation (operation time approx. 8 hours)
After successful surgery and a well-perfused transplant, the patient was postoperatively transferred to the intensive care unit intubated, ventilated and catecholamine-dependent (0.41 µg/kg/min with a mean arterial pressure of 65 mm/Hg)
Development of lactic acidosis (3.6 mmol/l)
Sharp increase in inflammation-relevant parameters (leukocytes 18,700/µl, CRP 13.5 mg/dl, IL-6 539 pg/ml)
Initiation of antibiotic therapy with 3g sultamicillin
Administration of hydrocortisone 20 mg/h + 3 Red Packed Blood Cells
Immediate initiation of continuous renal replacement therapy in combination with CytoSorb because of the anticipated risk of a complex infection due to the accident and the location of the accident (landfill)
Treatment
A total of 8 treatments with CytoSorb over 8 days with therapy intervals of 24 hours each were carried out (interrupted by surgical procedures)
CytoSorb was used in combination with CRRT (Multifiltrate, Fresenius Medical Care) in CVVHDF mode
Blood flow: 100 ml/min
Anticoagulation: Citrate
CytoSorb Adsorber position: pre-hemofilter
Measurements
Demand for catecholamines
Inflammatory parameters (CRP, IL-6, leucocytes)
Lactate
Results
Clear improvement in hemodynamics with reduction of catecholamine dosages
Significant reduction of inflammatory parameters, in particular IL-6 decreased from 1804 pg/ml to 20.1 pg/ml with CytoSorb therapy
Declining lactate values during the 8 treatments
Patient Follow-Up
During the course of the following week development of sepsis with multiple organ failure
Infection and necrosis of the amputate followed by removal of the necrotic tissue and ultimately amputation of the forearm
Continuous stabilization and improvement after amputation while still under CytoSorb for two more days
Daily surgical wound care, disinfection, removal of necrotic tissue
18 days after initial admission the patient was transferred to the normal trauma-surgical ward
Eventual adaptation of a robotic prosthesis and complete recovery of the patient
CONCLUSIONS
The early treatment with CytoSorb was accompanied by a relatively modest systemic inflammatory reaction which subsided without major or permanent organ damage, despite the impressive pathogen spectrum and the pronounced local damage
The early and continuous use of the CytoSorb adsorber was easy and safe for the entire staff of the intensive care unit
Recent CTSO News
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM